John M Bennett| - JoVE Visualize

Showing results (101-110 of 131) with videos related to

Pageof 14

Sort By:

Leukemia Research|January 30, 2007

Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conferencePeter Valent, Hans-Peter Horny, John M Bennett, et al.

Blood|January 13, 2016

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groupsMarlise R Luskin, Ju-Whei Lee, Hugo F Fernandez, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2021

Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant ErythropoietinAlan F List, Zhuoxin Sun, Amit Verma, et al.

Nature Communications|May 30, 2025

Identification of covalent inhibitors of Staphylococcus aureus serine hydrolases important for virulence and biofilm formationTulsi Upadhyay, Emily C Woods, Stephen Dela Ahator, et al.

Cancer|August 24, 2005

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrenceRichard A Larson, Eric L Sievers, Edward A Stadtmauer, et al.

Genes, Chromosomes & Cancer|September 25, 2018

Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significanceJulie Schanz, Francesc Solé, Mar Mallo, et al.

Blood|September 26, 2007

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qAzra Raza, James A Reeves, Eric J Feldman, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaBruce D Cheson, John M Bennett, Kenneth J Kopecky, et al.

Journal of the National Comprehensive Cancer Network : JNCCN|January 15, 2011

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromesPeter L Greenberg, Eyal Attar, John M Bennett, et al.

Leukemia & Lymphoma|February 28, 2015

Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997David M Lucas, Amy S Ruppert, Gerard Lozanski, et al.

Pageof 14

Showing results (101-110 of 131) with videos related to

Sort By:

Pageof 14

Leukemia Research|January 30, 2007

Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conferencePeter Valent, Hans-Peter Horny, John M Bennett, et al.

Blood|January 13, 2016

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groupsMarlise R Luskin, Ju-Whei Lee, Hugo F Fernandez, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2021

Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant ErythropoietinAlan F List, Zhuoxin Sun, Amit Verma, et al.

Nature Communications|May 30, 2025

Identification of covalent inhibitors of Staphylococcus aureus serine hydrolases important for virulence and biofilm formationTulsi Upadhyay, Emily C Woods, Stephen Dela Ahator, et al.

Cancer|August 24, 2005

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrenceRichard A Larson, Eric L Sievers, Edward A Stadtmauer, et al.

Genes, Chromosomes & Cancer|September 25, 2018

Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significanceJulie Schanz, Francesc Solé, Mar Mallo, et al.

Blood|September 26, 2007

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qAzra Raza, James A Reeves, Eric J Feldman, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaBruce D Cheson, John M Bennett, Kenneth J Kopecky, et al.

Journal of the National Comprehensive Cancer Network : JNCCN|January 15, 2011

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromesPeter L Greenberg, Eyal Attar, John M Bennett, et al.

Leukemia & Lymphoma|February 28, 2015

Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997David M Lucas, Amy S Ruppert, Gerard Lozanski, et al.

Pageof 14